2cureX AB Logo

2cureX AB

Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.

2CUREX | ST

Overview

Corporate Details

ISIN(s):
SE0010468124
LEI:
549300SFOL75WIYF2O80
Country:
Sweden
Address:
Box 159, 261 22 Landskrona
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

2cureX AB is a biotechnology company specializing in precision oncology through functional drug sensitivity testing. The company develops and commercializes the IndiTreat® family of tests, its core product line. IndiTreat® is the first CE-marked in-vitro diagnostic (IVD) test that utilizes patient-derived 3D tumoroids to predict individual responses to cancer treatments. This technology provides oncologists with personalized data to guide therapy selection, particularly for patients with metastatic colorectal cancer. The company's mission is to improve cancer treatment outcomes by matching specific therapies to individual patients, thereby enhancing the efficacy of oncological care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all 2cureX AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 2cureX AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 2cureX AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan 4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America TVRD
Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America TYRA
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America RARE

Talk to a Data Expert

Have a question? We'll get back to you promptly.